Candida prophylaxis and therapy in the ICU

Pablo M. Echeverria, Daniel H Kett, Elie Azoulay

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The incidence of invasive candidiasis in critically ill patients has increased over the past decade and is associated with considerable morbidity and mortality. Candida is identified in up to 17% of ICU patients, with candidemia occurring in 1%. Candida albicans continues to account for approximately half of the invasive candidiasis cases, with non-albicans Candida species, such Candida glabrata, increasing in frequency. Diagnosis of invasive candidiasis is commonly based on blood culture results; however, the sensitivity of blood culture to identify Candida is low. Because early, appropriate therapy has been associated with improved outcomes, antifungal therapy is being implemented in critically ill patients with risk factors for candidemia (prophylaxis). Systemic antifungal therapy is also being utilized in patients at increased risk for invasive candidiasis based on surrogate markers of infection such as colonization (preemptive therapy), or in patients with unresolving sepsis despite appropriate management (empirical therapy). Recent guidelines on the use of antifungal therapy have better identified patients who can be treated with azole derivatives and those who may benefit from echinocandins or polyenes. However, prospective trials are still needed to better identify appropriate therapy for patients at risk for, or with, confirmed invasive Candida infections.

Original languageEnglish
Pages (from-to)159-173
Number of pages15
JournalSeminars in Respiratory and Critical Care Medicine
Volume32
Issue number2
DOIs
StatePublished - Apr 26 2011

Fingerprint

Candida
Invasive Candidiasis
Candidemia
Critical Illness
Therapeutics
Echinocandins
Candida glabrata
Polyenes
Azoles
Secondary Prevention
Infection
Candida albicans
Sepsis
Biomarkers
Guidelines
Morbidity
Mortality
Incidence

Keywords

  • Candida
  • colonization
  • echinocandins
  • ICU
  • outcomes

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Candida prophylaxis and therapy in the ICU. / Echeverria, Pablo M.; Kett, Daniel H; Azoulay, Elie.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 32, No. 2, 26.04.2011, p. 159-173.

Research output: Contribution to journalArticle

Echeverria, Pablo M. ; Kett, Daniel H ; Azoulay, Elie. / Candida prophylaxis and therapy in the ICU. In: Seminars in Respiratory and Critical Care Medicine. 2011 ; Vol. 32, No. 2. pp. 159-173.
@article{eddf30d7490e4a4eae974ca12cfbcc1c,
title = "Candida prophylaxis and therapy in the ICU",
abstract = "The incidence of invasive candidiasis in critically ill patients has increased over the past decade and is associated with considerable morbidity and mortality. Candida is identified in up to 17{\%} of ICU patients, with candidemia occurring in 1{\%}. Candida albicans continues to account for approximately half of the invasive candidiasis cases, with non-albicans Candida species, such Candida glabrata, increasing in frequency. Diagnosis of invasive candidiasis is commonly based on blood culture results; however, the sensitivity of blood culture to identify Candida is low. Because early, appropriate therapy has been associated with improved outcomes, antifungal therapy is being implemented in critically ill patients with risk factors for candidemia (prophylaxis). Systemic antifungal therapy is also being utilized in patients at increased risk for invasive candidiasis based on surrogate markers of infection such as colonization (preemptive therapy), or in patients with unresolving sepsis despite appropriate management (empirical therapy). Recent guidelines on the use of antifungal therapy have better identified patients who can be treated with azole derivatives and those who may benefit from echinocandins or polyenes. However, prospective trials are still needed to better identify appropriate therapy for patients at risk for, or with, confirmed invasive Candida infections.",
keywords = "Candida, colonization, echinocandins, ICU, outcomes",
author = "Echeverria, {Pablo M.} and Kett, {Daniel H} and Elie Azoulay",
year = "2011",
month = "4",
day = "26",
doi = "10.1055/s-0031-1275528",
language = "English",
volume = "32",
pages = "159--173",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "2",

}

TY - JOUR

T1 - Candida prophylaxis and therapy in the ICU

AU - Echeverria, Pablo M.

AU - Kett, Daniel H

AU - Azoulay, Elie

PY - 2011/4/26

Y1 - 2011/4/26

N2 - The incidence of invasive candidiasis in critically ill patients has increased over the past decade and is associated with considerable morbidity and mortality. Candida is identified in up to 17% of ICU patients, with candidemia occurring in 1%. Candida albicans continues to account for approximately half of the invasive candidiasis cases, with non-albicans Candida species, such Candida glabrata, increasing in frequency. Diagnosis of invasive candidiasis is commonly based on blood culture results; however, the sensitivity of blood culture to identify Candida is low. Because early, appropriate therapy has been associated with improved outcomes, antifungal therapy is being implemented in critically ill patients with risk factors for candidemia (prophylaxis). Systemic antifungal therapy is also being utilized in patients at increased risk for invasive candidiasis based on surrogate markers of infection such as colonization (preemptive therapy), or in patients with unresolving sepsis despite appropriate management (empirical therapy). Recent guidelines on the use of antifungal therapy have better identified patients who can be treated with azole derivatives and those who may benefit from echinocandins or polyenes. However, prospective trials are still needed to better identify appropriate therapy for patients at risk for, or with, confirmed invasive Candida infections.

AB - The incidence of invasive candidiasis in critically ill patients has increased over the past decade and is associated with considerable morbidity and mortality. Candida is identified in up to 17% of ICU patients, with candidemia occurring in 1%. Candida albicans continues to account for approximately half of the invasive candidiasis cases, with non-albicans Candida species, such Candida glabrata, increasing in frequency. Diagnosis of invasive candidiasis is commonly based on blood culture results; however, the sensitivity of blood culture to identify Candida is low. Because early, appropriate therapy has been associated with improved outcomes, antifungal therapy is being implemented in critically ill patients with risk factors for candidemia (prophylaxis). Systemic antifungal therapy is also being utilized in patients at increased risk for invasive candidiasis based on surrogate markers of infection such as colonization (preemptive therapy), or in patients with unresolving sepsis despite appropriate management (empirical therapy). Recent guidelines on the use of antifungal therapy have better identified patients who can be treated with azole derivatives and those who may benefit from echinocandins or polyenes. However, prospective trials are still needed to better identify appropriate therapy for patients at risk for, or with, confirmed invasive Candida infections.

KW - Candida

KW - colonization

KW - echinocandins

KW - ICU

KW - outcomes

UR - http://www.scopus.com/inward/record.url?scp=79955047334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955047334&partnerID=8YFLogxK

U2 - 10.1055/s-0031-1275528

DO - 10.1055/s-0031-1275528

M3 - Article

C2 - 21506052

AN - SCOPUS:79955047334

VL - 32

SP - 159

EP - 173

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 2

ER -